Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...

Life Molecular Imaging (LMI), an international pharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging, announces that the U.S. Food and ...

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human ...

The drug has been granted Breakthrough Therapy designation by the FDA for the treatment of chronic hepatitis delta (CHD).

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced ...

Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from its Phase I/II CLINCH study ongoing in China and Australia evaluating ATN-022 ...

The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the ...

Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experienceSOUTH SAN FRANCISCO, Calif., ...

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”) ...

Breakthrough Therapy Designation is designed to expedite the development and review of therapies that may show significant improvement over available ...

SAN DIEGO - Inhibrx Biosciences, Inc. (NASDAQ: INBX), a clinical-stage biopharmaceutical company valued at $195 million, ...

Mo Qatanani, the Chief Scientific Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), executed a sale of 7,347 shares of common stock, according to a recent SEC filing. The shares were sold at an ...